Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Minor Surgeries Safe for Hemophilia Patients on Emicizumab

Key clinical point: Minor surgery in patients taking emicizumab for hemophilia A may not require prophylactic coagulation factor therapy.

Major finding: Among hemophilia A patients receiving emicizumab and undergoing minor surgery, 90.8% did not experience a postoperative bleed requiring treatment.

Study details: Analysis of data from four HAVEN studies and involving 399 patients with hemophilia A.

Disclosures: The study was funded by F. Hoffman-La Roche and Chugai Pharmaceutical. Dr. Santagostino reported consultancies and speakers bureau engagements with the pharmaceutical sector.

Citation:

Santagostino E et al. 2019 ISTH Congress, Abstract OC 60.1.